uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Regional intestinal drug permeation: Biopharmaceutics and drug development
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacy.
2014 (English)In: European Journal of Pharmaceutical Sciences, ISSN 0928-0987, E-ISSN 1879-0720, Vol. 57, no SI, 333-341 p.Article, review/survey (Refereed) Published
Abstract [en]

Over the last 25 years, profound changes have been seen in both the development and regulation of pharmaceutical dosage forms, due primarily to the extensive use of the biopharmaceutical classification system (BCS) in both academia and industry. The BCS and the FDA scale-up and post-approval change guidelines were both developed during the 1990s and both are currently widely used to claim biowaivers. The development of the BCS and its wide acceptance were important steps in pharmaceutical science that contributed to the more rational development of oral dosage forms. The effective permeation (P-eff) of drugs through the intestine often depends on the combined outcomes of passive diffusion and multiple parallel transport processes. Site-specific jejunal P-eff cannot reflect the permeability of the whole intestinal tract, since this varies along the length of the intestine, but is a useful approximation of the fraction of the oral dose that is absorbed. It appears that drugs with a jejunal P-eff > 1.5 x 10(-4) cm/s will be completely absorbed no matter which transport mechanisms are utilized. In this paper, historical clinical data originating from earlier open, single-pass perfusion studies have been used to calculate the P-eff of different substances from sites in the jejunum and ileum. More exploratory in vivo studies are required in order to obtain reliable data on regional intestinal drug absorption. The development of experimental and theoretical methods of assessing drug absorption from both small intestine and various sites in the colon is encouraged. Some of the existing human in vivo data are discussed in relation to commonly used cell culture models. It is crucial to accurately determine the input parameters, such as the regional intestinal P-eff, as these will form the basis for the expected increase in modeling and simulation of all the processes involved in GI drug absorption, thus facilitating successful pharmaceutical development in the future. It is suggested that it would be feasible to use open, single-pass perfusion studies for the in vivo estimation of regional intestinal TV, but that care should be taken in the study design to optimize the absorption conditions.

Place, publisher, year, edition, pages
2014. Vol. 57, no SI, 333-341 p.
Keyword [en]
Biopharmaceutics, Biopharmaceutical classification system, PBPK, IVIVC, Dissolution, Drug absorption
National Category
Pharmacology and Toxicology
URN: urn:nbn:se:uu:diva-228425DOI: 10.1016/j.ejps.2013.08.025ISI: 000336471400031OAI: oai:DiVA.org:uu-228425DiVA: diva2:734163
Available from: 2014-07-15 Created: 2014-07-14 Last updated: 2014-07-15Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Lennernas, Hans
By organisation
Department of Pharmacy
In the same journal
European Journal of Pharmaceutical Sciences
Pharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 166 hits
ReferencesLink to record
Permanent link

Direct link